Down's syndrome: Protection against cancer and the therapeutic potential of DSCR1

Future Oncology

Volumn 5, Issue 8, 2009, Pages 1185-1188

  Ryeom, Sandra ^a   Baek, Kwan Hyuck ^a   Zaslavsky, Alexander ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; COLLAGEN TYPE 13; CYCLOSPORIN A; DOWN SYNDROME CANDIDATE REGION 1; GENE PRODUCT; PROTEIN DYRK1A; TACROLIMUS; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER INCIDENCE; CHROMOSOME 21; DISEASE ASSOCIATION; DOWN SYNDROME; EDITORIAL; GENE CONTROL; GENE FUNCTION; GENE LOCATION; GENE TARGETING; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRISOMY 21; TUMOR VASCULARIZATION;

DOWN SYNDROME; HUMANS; NEOPLASMS;

EID: 75649131127     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.88     Document Type: Editorial

References (24)

1. Dvorak HF: Vascular permeability factor/ vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20, 4368-4380 (2002).
2. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat. Med. 9, 669-676 (2003).
3. Hernandez GL, Volpert OV, Iniguez MA et al.: Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporine A: roles of the nuclear factor of activated T cells and cyclooxygenase2. J. Exp. Med. 193, 607-620 (2001).
4. Johnson EN, Lee YM, Sander TL et al.: NFATc1 mediates vascular endothelial growth factor-induced proliferation of human pulmonary valve endothelial cells. J. Biol. Chem. 278, 1686-1692 (2003).
5. Ryeom S, Baek KH, Rioth MJ et al.: Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth. Cancer Cell 13, 420-431 (2008).
6. Hesser BA, Liang XH, Camenisch G et al.: Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells. Blood 104, 149-158 (2004).
7. Iizuka M, Abe M, Shiiba, K, Sasaki, I, Sato Y: Down syndrome candidate region1, a downstream target of VEGF, participates in endothelial cell migration and angiogenesis. J. Vasc. Res. 41, 334344 (2004).
8. Minami T, Horiuchi K, Miura M et al.: Vascular endothelial growth factor-and thrombin-induced termination factor, Down syndrome critical region-1, attenuates endothelial cell proliferaration and angiogenesis. J. Biol. Chem. 279, 50537-50554 (2004).
9. Yao YG, Duh EJ: VEGF selectively induces Down syndrome critical region 1 gene expression in endothelial cells: a mechanism for feedback regulation of angiogenesis? Biochem. Biophys. Res. Comm. 321, 648-656 (2004).
10. Yang Q, Rasmussen SA, Freidman JM: Mortality associated with Down's syndrome in the USA from 1982 to 1997: a population-based study. Lancet 359, 1019-1025 (2002). ■■ Examines mortality due to cancer in over 17,000 Down's syndrome individuals compared with non-Down's syndrome individuals.
11. Black WC, Welch HG: Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N. Engl. J. Med. 328, 1237-1243 (1993). ■ Suggests that the incidence of carcinoma in situ is significantly underestimated.
12. Baek KH, Zaslavsky A, Lynch RC et al.: Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature 459, 1126-1130 (2009). ■■ Demonstrates that DSCR1 plays a significant role in cancer protection in mouse models of Down's syndrome by suppressing tumor angiogenesis.
13. O'Reilly MS, Boehm T, Shing Y et al.: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285 (1997).
14. Zorick TS, Mustacchi Z, Bando SY et al.: High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. Eur. J. Hum. Genet. 9, 811-814 (2001). ■ Demonstrates high levels of the circulating endogenous angiogenesis inhibitor, endostatin, in Down's syndrome individuals.
15. Iruela-Arispe ML, Carpizo D, Luque A: ADAMTS1: a matrix metalloprotease with angioinhibitory properties. Ann. NY Acad. Sci. 995, 183-190 (2003).
16. Miguel RF, Pollak A, Lubec G: Metalloproteinase ADAMTS-1 but not ADAMTS-5 is manifold overexpressed in neurodegenerative disorders as Down syndrome, Alzheimer's and Pick's disease. Brain Res. Mol. Brain Res.133, 1-5 (2005).
17. Arron JR, Winslow MM, Polleri A et al.: NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature 441, 595-600 (2006).
18. Gwack Y, Sharma S, Nardone J et al.: A genome-wide Drosophila RNAi screen identifieds DYRK-family kinases as regulators of NFAT. Nature 441, 646-650 (2006).
19. Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C, St Croix B: Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 11, 539-554 (2007).
20. London NJ, Farmery SM, Will EJ, Davison M, Lodge JP: Risk of neoplasia in renal transplant patients. Lancet 346, 403-406 (1995).
21. Dantal J, Hourmant M, Cantarovich D et al.: Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomized comparison of two cyclosporine regimens. Lancet 351, 623-628 (1998).
22. Hojo M, Morimoto T, Maluccio M et al.: Cyclosporin induces cancer progression by a cell-autonomous mechanism. Nature 397, 530-534 (1999).
23. Kissinger CR, Parge HE, Knighton DR et al.: Crystal structures of human calcineurin and the human FKBP12-FK506-calcineurin complex. Nature 378, 641-644 (1995).
24. Ke H, Huai Q: Structures of calcineurin and its complexes with immunophilins-immunosuppressants. Biochem. Biophys. Res. Comm. 311, 1095-1102 (2003).